Dr Martin Reck talks to ecancer at ESMO 2018 about the latest research for advanced non small cell lung cancer.

He first discusses tyrosine kinase inhibitors, MET alterations, and the improvement of immunotherapies particularly in combination with checkpoint inhibitors.

Dr Reck goes in to more detail about some trials testing these treatments, and potential avenues for the future.

For more on NSCLC, watch Dr Enriqueta Felip discuss advances reported at the conference here.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.